The Fyn kinase inhibitor, AZD0530, suppresses mouse alcohol self-administration and seeking

Area of Science:

• Neuroscience
• Pharmacology
• Addiction Research

Background:

• Fyn, a protein tyrosine kinase (PTK), is implicated in synaptic function and brain disorders like alcohol use disorder (AUD).
• Previous studies show Fyn activation in the dorsomedial striatum (DMS) during alcohol withdrawal contributes to alcohol consumption and relapse.

Purpose of the Study:

• To evaluate the efficacy of AZD0530, a CNS-penetrant Src PTK inhibitor, in mitigating alcohol-induced molecular and behavioral changes.
• To investigate the potential of AZD0530 as a therapeutic agent for alcohol use disorder.

Main Methods:

• Systemic administration of AZD0530 in mice models of alcohol use.
• Assessment of Fyn activation and GluN2B phosphorylation in the DMS.
• Evaluation of alcohol operant self-administration and locomotion behaviors.
• Analysis of dopamine D1 receptor-dependent locomotion.

Main Results:

• AZD0530 administration prevented alcohol-induced Fyn activation and GluN2B phosphorylation in the DMS.
• A single dose of AZD0530 decreased alcohol self-administration and promoted extinction of this behavior.
• AZD0530 did not alter basal or dopamine D1 receptor-dependent locomotion.

Conclusions:

• AZD0530 effectively inhibits Fyn kinase activity in the brain.
• Targeting Fyn signaling with AZD0530 shows potential for reducing alcohol seeking and consumption.
• AZD0530 represents a promising therapeutic strategy for alcohol use disorder.